3 medtech spinoffs that reshaped the industry in 2023, and what to expect next

GE HealthCare, Johnson & Johnson and Danaher completed transactions this year. Baxter, 3M and Medtronic are now on deck.

By Susan Kelly • Nov. 29, 2023

Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant

Bioventus’ protracted buyout bid ultimately fell apart and opened the door to Smith & Nephew.

By Nick Paul Taylor • Nov. 27, 2023

4 takeaways from Stryker’s investor day

The company’s expected return to pre-pandemic operating margins, procedure backlogs and weight loss drugs were among the topics discussed at Wednesday’s event.

By Elise Reuter • Nov. 9, 2023

Inari Medical to buy limb-saving device maker LimFlow for up to $415M

The deal includes $250 million in cash upfront and additional payments based on reaching commercial and reimbursement milestones.

By Susan Kelly • Nov. 3, 2023

CooperCompanies buys reproductive health products from Cook Medical after failed takeover

The company paid $300 million to buy certain maternal fetal medicine and gynecological surgery products. 

By Elise Reuter • Nov. 2, 2023

Thermo Fisher buys Olink Holding for $3.1B, pushing further into proteomics

Olink’s high-throughput protein analysis technology is expected to complement Thermo Fisher’s mass spectrometry and life sciences platforms.

By Susan Kelly • Oct. 17, 2023

Illumina details EC timeline, funding requirements for Grail divestment

The European Commission ordered the gene sequencing company to support Grail with two-and-a-half years of funding if it pursues a spinoff.

By Susan Kelly • Oct. 13, 2023

Getinge inks $320M Healthmark takeover to bolster US sterile reprocessing capabilities

Buying Healthmark strengthens the position of Getinge in the U.S., building on two recent acquisitions of sterile reprocessing technology.

By Nick Paul Taylor • Oct. 12, 2023

How Medtronic, Zimmer Biomet and Smith & Nephew are thinking about acquisitions, spinoffs

Executives from the three medical device firms said they expect more deal-making in the long term, but face tough discussions about valuations with targets.

By Elise Reuter • Oct. 11, 2023

Haemonetics inks $253M OpSens buyout, adding cardiology guidewires to portfolio

The takeover will give Haemonetics devices that complement its vascular closure products, analysts said.

By Nick Paul Taylor • Oct. 11, 2023

5 financial challenges facing the medtech sector: EY

Declining stock prices, M&A, investment and revenues are dogging the industry in a difficult year, according to a new report from the consulting firm.

By Elise Reuter • Oct. 10, 2023

J&J could reach market-leading medtech growth after consumer spinoff: analysts

The analysts identified J&J’s leadership position in 11 categories, shift to fast-growing markets and investment in robotics as strengths.

By Nick Paul Taylor • Oct. 9, 2023

Labcorp buys Baystate’s outreach lab business, furthering consolidation blitz

The deal, Labcorp’s fourth outreach takeover since May, will give the company control of service centers in Massachusetts.

By Nick Paul Taylor • Oct. 5, 2023

Medtronic in exclusive talks for $7B sale of units to private equity: report

The Carlyle Group is leading the race to buy Medtronic’s connected patient monitoring and respiratory care operations, Reuters reported.

By Nick Paul Taylor • Oct. 2, 2023

Siemens Healthineers buys Aspekt to bolster radiation oncology services

The company’s Varian unit sees Aspekt as complementary to its Advanced Oncology Solutions business, which provides professional and clinical services.

By Nick Paul Taylor • Sept. 27, 2023

Enovis inks $847M acquisition to boost orthopedic reconstruction business

A Wells Fargo analyst said the deal was “much larger than what we were expecting.”

By Nick Paul Taylor • Sept. 26, 2023

Is bigger better? McKinsey predicts the return of large medtech mergers

The analysts argue that pressure to improve margins and become the partner of choice to hospitals favors large deals.

By Nick Paul Taylor • Sept. 22, 2023

Boston Scientific to buy back pain treatment company Relievant for $850M

The company, which makes a treatment for chronic back pain, is expected to bring in more than $70 million in sales this year.

By Elise Reuter • Sept. 19, 2023

Bigfoot CEO talks Abbott acquisition, future of diabetes tech

Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.

By Elise Reuter • Sept. 15, 2023

FTC closes probe of Resonetics’ $900M medical nitinol purchase

The acquisition would give Resonetics a leading supplier of the alloy for the medical device industry.

By Elise Reuter • Sept. 14, 2023

Bausch + Lomb seeks funding for $1.75B eye drop acquisition from Novartis

Fitch Ratings called the deal to buy the Xiidra treatment “strategically sound” even as the company’s plan to fund it would increase its leverage.

By Nick Paul Taylor • Sept. 12, 2023

Abbott to buy smart insulin pen cap maker Bigfoot

The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.

By Elise Reuter • Sept. 6, 2023

Danaher to buy antibody supplier Abcam for $5.7B

The acquisition gives Danaher an entry into the protein consumables market, Stifel analysts said.

By Elise Reuter • Aug. 28, 2023

VC funding in medtech ticks up, raising hopes that slump has bottomed

Analysts also forecast renewed interest in M&A now that large companies have worked through a string of spinoffs.

By Nick Paul Taylor • Aug. 25, 2023

Agilent to wind down Resolution Bioscience liquid biopsy unit

The company will discontinue operations at the business it bought two years ago for $550 million.

By Susan Kelly • Aug. 21, 2023